Yatharth Hospital & Trauma Care Services Limited (NSE:YATHARTH)
India flag India · Delayed Price · Currency is INR
837.85
+8.10 (0.98%)
Jul 13, 2026, 10:40 AM IST

Yatharth Hospital & Trauma Care Services Earnings Call Transcripts

Fiscal Year 2026

  • Q4 25/26

    FY 2026 saw 36% YoY revenue growth and 30% EBITDA growth, driven by new hospital ramp-ups, clinical excellence, and strategic expansion. Margin guidance remains at 24-25% for FY 2027, with revenue growth expected to surpass FY 2026. Net cash position is strong, supporting further expansion.

  • Q3 25/26

    Q3 FY26 saw record revenue and profitability, driven by strong growth in both existing and new hospitals, with ARPOB and EBITDA margins improving year-over-year. Expansion plans target 5,000 beds in 3 years, with a focus on super specialties, reduced government mix, and enhanced operational efficiency.

  • Q2 25/26

    Record revenue and EBITDA growth driven by new hospital additions and mature facility performance, with strong ARPOB and occupancy rates. Expansion continues with new acquisitions, advanced clinical technologies, and a robust balance sheet, while CGHS rate revision and GST cuts are set to boost profitability.

  • Q1 25/26

    Q1 FY 2026 saw record revenue and profit, with 22% YoY revenue growth and 23% net profit growth, driven by new hospital ramp-ups and super specialty focus. New Delhi and Faridabad hospitals are set to boost growth, with EBITDA margins expected to remain around 24%-25% for FY 2026.

Fiscal Year 2025

  • Q4 24/25

    FY 2025 saw a 4.6% revenue decline due to payment delays and project award lags, but EBITDA margin improved to 12.8% and PAT rose 8%. The order book hit a record INR 36,869 crore, with strong growth and margin guidance for FY 2026.

  • Q3 24/25

    Revenue grew 31% YoY in Q3 FY2025, with strong EBITDA and ARPOB gains driven by super-specialty and oncology expansion. Two major hospital acquisitions are set to boost capacity, while income tax asset blocks are expected to resolve soon without material impact.

  • Q2 24/25

    Revenue grew 34% year-over-year to INR 1,713 million, with profit after tax up 70% and EBITDA margin at 26.6%. IPO proceeds enabled debt repayment and expansion plans, while super-specialty and international business are set to drive future growth.

Fiscal Year 2024